TrialEuropean journal of clinical pharmacology2006

Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.

Lauri I Kajosaari et al.PubMed ↗Publisher ↗

No numbers read from the abstract.